ATYR

Atyr Pharma, Inc. is a biotechnology company focused on developing therapeutics based on its proprietary tRNA synthetase biology platform. The company is engaged in research and development of treatments for rare diseases, with a particular emphasis on pulmonary sarcoidosis and systemic sclerosis-associated interstitial lung disease (SSc-ILD). Atyr Pharma operates primarily in the United States and is involved in clinical trials to advance its drug candidates.